EGF Receptor / EGFR Antibody (cytoplasmic domain)

Biorbyt

EGF Receptor / EGFR Antibody (cytoplasmic domain)

10

Titration of the antibody may be required for optimal performance.1. This antibody reacts with a cytoplasmic domain of EGFR.

ImmunoPrecipitation, Western Blot

Immunoprecipitation: 1-2ug/500ug protein lysate,Western blot: 0.5-1ug/ml for 2 hours at RT IP, WB

Research Use Only

Monoclonal

H9B4

Unconjugated

EGFR

epidermal growth factor receptor

ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS, PIG61, mENA, epidermal growth factor receptor, EGFR vIII, avian erythroblastic leukemia viral (v-erb-b) oncogene homolog, cell growth inhibiting protein 40, cell proliferation-inducing protein 61, epidermal growth factor receptor tyrosine kinase domain, erb-b2 receptor tyrosine kinase 1, proto-oncogene c-ErbB-1, receptor tyrosine-protein kinase erbB-1

Mouse

IgG1

Epidermal Growth Factor Receptor is a type I receptor tyrosine kinase, referred to as EGFR, ErbB1 and HER1. When EGFR is activated by one of its ligands, it dimerizes. It can form a homodimer, heterodimers with other ErbB family members, or even a cluster of EGFRs. Activation stimulates EGFRs intracellular kinase activity. Autophosphorylation of tyrosine residues in the C-terminal domain of EGFR leads to association with proteins with phosphotyrosine-binding domains which then signal the initiation of signal transduction cascades including the JNK, MAPK, AKT, and possibly Nf-KB, pathways. Overexpression of EGFR is the cause of some types of cancer, including lung and colon cancer. It has also been linked to psoriasis, eczema and atherosclerosis, although poorly defined. Monoclonal antibody to EGFR can be used to block the extracellular ligand binding domain, therebye blocking tyrosine kinase activation and subsequent signal transduction.

Human

-20°C,2°C to 8°C

12352203